Lars Fruergaard Jørgensen has been the CEO of the company, a period during which the company has grown to be one of Europe's largest thanks to the medicines Wegovy and Ozempic, which have proven to be effective for weight reduction.
About a year ago, however, the stock price has plummeted 53 percent in connection with, among other things, increased competition, primarily from American Eli Lilly. In the press release, the company writes that "a CEO change lies in the company's and shareholders' interest".
No new CEO has yet been appointed, but the company states that it is looking for a suitable candidate and Lars Fruergaard Jørgensen remains in his position until a new CEO has been recruited.
Today's announcement causes the stock to fall by around 2 percent.
